Trial
NCT05359081
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sumitomo Pharma Co., Ltd.
Collaborators
—
Condition
Schizophrenia
Intervention
SEP-363856
Why stopped
Due to company business strategy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-19